Contact this trialFirst, we need to learn more about you.
AZD9977 +1 More for Chronic Kidney Disease
Recruiting1 awardPhase 2
Columbus, Georgia
This trial tests a new drug, AZD9977, combined with dapagliflozin in patients with heart failure and chronic kidney disease. The goal is to see if this combination improves kidney function and heart health better than using dapagliflozin alone. Dapagliflozin is a medication that has been shown to reduce heart-related deaths and heart failure in patients with chronic heart failure.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service